Secondary leukaemia after testicular germ cell tumour treatment: a systematic review and meta-analysis.
Level 3 - non-randomized controlled study
Systematic review and meta-analysis of observational cohort studies
PubMed 42117759 · doi:10.1111/bju.70315
What was done
A systematic review and meta-analysis of studies in MEDLINE, EMBASE, and the Cochrane Library investigating secondary leukaemia incidence following testicular germ cell tumour (TGCT) treatment compared to the general population. Data were pooled using random-effects models reporting standardised incidence ratios (SIRs), and certainty was assessed with GRADE.
What was found
Across 6 included studies with 57,365 patients and 163 secondary leukaemias (weighted-mean follow-up 12.8 years), chemotherapy was associated with an increased risk of secondary leukaemia (SIR 5.77, 95% CI 1.35–24.62; P = 0.03). Radiation therapy was not significantly associated with increased risk (SIR 2.55, 95% CI 0.70–9.32; P = 0.11). Absolute risk remained low.
Why it matters
Because TGCTs affect young men and carry high cure rates, quantifying long-term treatment-related toxicities helps guide therapeutic choice and post-treatment surveillance.
Limits
Only six studies were included, resulting in wide confidence intervals for both effect estimates. The abstract does not break down risks by specific chemotherapy agents, cumulative dose, stage, or leukaemia subtype.
Cited by
- supports Radiation and chemotherapy treatments are major risk factors for cancer recurrence and the development of secondary malignancies.